Article Complete
AIM
Bristol Myers Squibb, Accenture Launch AI-Powered Content Hub in Mumbai
Bristol Myers Squibb, Accenture Launch AI-Powered Content Hub in Mumbai
Pharma-Driven Disruption

Bristol Myers Squibb, Accenture Launch AI-Powered Content Hub in Mumbai

Mosaic is part of Bristol Myers Squibb’s broader $130-million investment in AI initiatives and AI-enabled capabilities across marketing

Published Updated

Key takeaways

  • Bristol Myers Squibb and Accenture launch Mosaic, an AI-powered content hub in Mumbai.
  • Mosaic aims to enhance BMS's global commercialization through real-time physician education and patient-centric content.
  • The initiative is part of BMS's $130-million investment in AI capabilities across marketing.
  • BMS leverages India's digital expertise to scale AI-driven solutions for its global operations.
  • The partnership between BMS and Accenture has evolved into a deep digital transformation collaboration over 25 years.
5 min

Bristol Myers Squibb (BMS), a biopharmaceutical company, in partnership with global professional services firm Accenture, has opened Mosaic, a first-of-its-kind, end-to-end generative AI-enabled content hub in Mumbai.

Designed to accelerate BMS’s global commercialisation efforts, the Mosaic hub will strengthen digital capabilities by identifying physicians’ educational needs in real-time and enabling the rapid creation of patient-centric content at scale.

“The future of healthcare is about meeting clinicians and patients where they are and doing so in meaningful ways. This partnership reflects our BMS approach to end-to-end digital transformation,” Adam Lenkowsky, chief commercialisation officer, Bristol Myers Squibb, said in a statement. 

Mosaic is part of Bristol Myers Squibb’s broader $130-million investment in AI initiatives and AI-enabled capabilities across marketing. The company is leveraging India’s collaborative ecosystem and deep digital expertise to develop and scale next-generation, AI-driven solutions for its global operations.

BMS has maintained a strong presence in India for over two decades through its commercial operations, delivering therapies in oncology, haematology, and cardiology. 

Recently, the company also opened a large facility in Hyderabad, employing more than 3,000 professionals across business insights and technology, global drug development, global product development and supply, and enabling functions.

The Mosaic initiative builds on the 25-year partnership between Bristol Myers Squibb and Accenture, which has evolved from traditional service delivery into a deep digital transformation collaboration. Through the Mumbai hub, the two companies will bring together a large team of creatives and technologists to modernise and reinvent how marketing content is developed and delivered globally.

“Accenture and Bristol Myers Squibb are leading the AI-forward reinvention of biopharma by applying innovative technologies to generate meaningful outcomes for patients,” said Ndidi Oteh, CEO, Accenture Song.

Membership

Stay ahead with AI insights.

Unlimited access to premium articles, exclusive analysis, and the stories shaping India's AI economy.

Subscribe now

AIM Americas

1190 Miraloma Way Suite P, Sunnyvale, CA 94085

AIM India

1st Floor, Sakti Statesman, Bellandur, Bengaluru – 560103

© 2026 AIM. All rights reserved.